Skip to main content

Table 2 A univariate Cox regression and a variable selection logistic regression for confounding factors based on Transfusion and No-transfusion

From: Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Characteristic

Variables

Before PSM

Univariate (OS, COX Regression)

Univariate (DFS, COX Regression)

Univariate (Logistic Regression)

Multivariate (Logistic Regression)

HR (95% CI)

P valuea

HR (95% CI)

P valuea

OR (95% CI)

P valuea

OR (95% CI)

P valuea

Age

Y ± SD

1.007 (0.998–1.017)

0.131

1.006 (0.997–1.014)

0.219

0.993 (0.973–1.013)

0.477

  

Gender

female

reference

0.121

reference

0.145

reference

0.009

reference

0.506

male

1.184 (0.956–1.466)

 

1.163 (0.949–1.425)

 

0.553 (0.355–0.863)

 

0.790 (0.393–1.585)

 

Preoperative Hb

g/L ± SD

0.988 (0.981–0.994)

<0.001

0.990 (0.985–0.996)

0.001

0.951 (0.937–0.965)

<0.001

0.947 (0.927–0.967)

<0.001

Platelet

1 × 109/L ± SD

1.001 (1.000–1.003)

0.177

1.001 (0.999–1.002)

0.222

1.004 (1.001–1.007)

0.006

1.001 (0.997–1.006)

0.537

Total bilirubin

umol/L + SD

1.003 (1.002–1.004)

<0.001

1.002(1.001–1.003)

0.001

1.007 (1.005–1.010)

<0.001

1.006 (1.003–1.009)

<0.001

AST

U/L ± SD

1.000 (0.999–1.002)

0.487

1.001 (1.000–1.002)

0.205

1.001 (0.999–1.003)

0.24

  

ALT

U/L ± SD

1.001 (1.000–1.002)

0.029

1.001 (1.000–1.002)

0.049

1.001 (0.999–1.003)

0.472

  

AFP

ng/mL ± SD

1.000 (1.000–1.000)

0.379

1.000 (1.000–1.000)

0.451

1.000 (1.000–1.000)

0.983

  

CEA

ng/mL ± SD

1.000 (1.000–1.000)

0.745

1.001 (1.000–1.001)

0.01

1.001 (1.000–1.002)

0.108

  

CA19–9

U/mL ± SD

1.000 (1.000–1.000)

<0.001

1.000 (1.000–1.000)

<0.001

1.000 (1.000–1.000)

<0.001

1.000 (1.000–1.000)

0.903

PT

s ± SD

1.000 (0.988–1.012)

0.99

1.008 (0.994–1.022)

0.28

1.007 (0.986–1.028)

0.507

  

INR

Value ±SD

2.307 (0.949–5.605)

0.065

1.692 (0.742–3.855)

0.211

0.714 (0.095–5.388)

0.744

  

HBsAg

(−)

reference

0.401

reference

0.232

reference

0.003

reference

0.126

(+)

0.912 (0.737–1.130)

 

0.882 (0.718–1.084)

 

0.459 (0.275–0.764)

 

0.552 (0.258–1.183)

 

Anti-HCV

(−)

reference

0.04

reference

0.076

reference

0.814

  

(+)

0.395 (0.163–0.956)

 

0.507 (0.240–1.073)

 

1.204 (0.256–5.663)

  

Tumor number

1

reference

0.446

reference

0.559

reference

0.261

  

>1

1.122 (0.835–1.507)

 

1.088 (0.821–1.441)

 

0.681 (0.348–1.332)

  

TMD

cm

1.052 (1.017–1.087)

0.003

1.057 (1.025–1.090)

<0.001

1.041 (0.975–1.113)

0.229

  

TNM stage

I

reference

<0.001

reference

0.001

reference

0.784

  

II

1.105 (0.804–1.518)

 

1.192 (0.882–1.611)

 

1.173 (0.624–2.206)

   

III

2.167 (1.104–4.255)

 

1.823 (0.961–3.455)

 

0.000(0.000-.)

   

IVa

2.088 (1.592–2.739)

 

1.657 (1.273–2.157)

 

0.766 (0.390–1.503)

   

Cirrhotic nodule

no

reference

0.274

reference

0.799

reference

0.067

  

yes

1.127 (0.910–1.397)

 

1.028 (0.834–1.266)

 

0.614 (0.365–1.035)

   

DD

I

reference

0.982

reference

0.997

reference

1.000

  

II-III

2997.401 (0.000-.)

 

8142.694 (0.000-.)

 

300,921,742.177 (0.000-.)

 

IV

2632.881 (0.000-.)

 

8450.077 (0.000-.)

 

1.000 (0.000-.)

   

IBL

<1000 mL

reference

0.005

reference

0.002

reference

<0.001

reference

<0.001

≥1000 mL

1.733 (1.184–2.535)

 

1.816 (1.243–2.652)

 

65.443 (22.383–191.341)

168.205 (43.249–654.184)

 

Preventive TACE

no

reference

0.349

reference

0.144

reference

0.972

  

yes

0.841 (0.585–1.209)

 

1.300 (0.914–1.848)

 

1.015 (0.439–2.348)

  
  1. OS: overall survival; DFS: disease-free survival; OR: odd ratio; HR: hazard ratio; “.”: indicate the exceeded value
  2. alikelihood ratio test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us